All In Biotech

Drug Trial Radar · NCT04686682

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors

Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

May 7, 2021

Primary completion

Jan 2028

Study completion Jul 2028

Sponsor

Sponsor type
Industry
First posted
Dec 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study. These two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.

Conditions

  • NSCLC
  • SCLC
  • CRPC
  • ESCC
  • Ovarian Carcinoma
  • AML
  • MF
  • Malignant Tumor

Interventions

  • JAB-8263Drug

    Variable dose, orally Q2D with 28 days each cycle

  • JAB-8263Drug

    RP2D dose, orally Q2D with 28 days each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicitiesTime frame: Approximately 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.